| Literature DB >> 25362245 |
Brian D Henry1, Daniel R Neill2, Katrin Anne Becker3, Suzanna Gore2, Laura Bricio-Moreno2, Regan Ziobro1, Michael J Edwards4, Kathrin Mühlemann5, Jörg Steinmann6, Burkhard Kleuser7, Lukasz Japtok7, Miriam Luginbühl8, Heidi Wolfmeier8, André Scherag9, Erich Gulbins1, Aras Kadioglu2, Annette Draeger8, Eduard B Babiychuk8.
Abstract
Gram-positive bacterial pathogens that secrete cytotoxic pore-forming toxins, such as Staphylococcus aureus and Streptococcus pneumoniae, cause a substantial burden of disease. Inspired by the principles that govern natural toxin-host interactions, we have engineered artificial liposomes that are tailored to effectively compete with host cells for toxin binding. Liposome-bound toxins are unable to lyse mammalian cells in vitro. We use these artificial liposomes as decoy targets to sequester bacterial toxins that are produced during active infection in vivo. Administration of artificial liposomes within 10 h after infection rescues mice from septicemia caused by S. aureus and S. pneumoniae, whereas untreated mice die within 24-33 h. Furthermore, liposomes protect mice against invasive pneumococcal pneumonia. Composed exclusively of naturally occurring lipids, tailored liposomes are not bactericidal and could be used therapeutically either alone or in conjunction with antibiotics to combat bacterial infections and to minimize toxin-induced tissue damage that occurs during bacterial clearance.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25362245 DOI: 10.1038/nbt.3037
Source DB: PubMed Journal: Nat Biotechnol ISSN: 1087-0156 Impact factor: 54.908